StreetInsider.com News Articles

Cellectar reports Phase 2b subgroup data for iopofosine I 131 in WM

Thu, 15 Oct 2026 07:01:02 -0400

Cellectar Biosciences (NASDAQ: CLRB) presented subgroup analysis data from its Phase 2b CLOVER WaM clinical trial at the International Workshop for Waldenström Macroglobulinemia, held October 14–16, 2026, in Palm Springs, California.

The analysis examined 24 patients with relapsed or refractory Waldenström macroglobulinemia (WM) who received iopofosine I 131 immediately following Bruton Tyrosine Kinase inhibitor (BTKi) therapy. Among the group, 75% were BTKi refractory, more than 54% had received multiple BTKi therapies, and patients had a median of three prior lines of therapy.

Key findings from the subgroup included an overall response rate of 87.5%, a major response rate of 79.2%, a clinical

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Works

Thu, 15 Oct 2026 07:00:00 -0400

Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months

Initiation and site selections for Phase 3 confirmatory randomized clinical trial in post-first line, post-BTKi population evaluating Progression-Free Survival as primary endpoint underway; dosing of first patients expected in 1Q27 and application for U.S. accelerated market approval anticipated in 1H27

FLORHAM PARK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Works

Thu, 15 Oct 2026 07:00:00 -0400

FLORHAM PARK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the

Cellectar to present Phase 2 iopofosine data at WM workshop

Tue, 29 Sep 2026 07:30:31 -0400

Cellectar Biosciences (NASDAQ: CLRB) announced it will present a subset analysis from its Phase 2 CLOVER WaM clinical trial at the International Workshop for Waldenström Macroglobulinemia (IWWM), scheduled for October 14–16, 2026, in Palm Springs, California.

The subset analysis examined patients with Waldenström Macroglobulinemia (WM) who received iopofosine I 131 immediately following BTK inhibitor therapy after at least two prior lines of treatment. The data showed a major response rate of 79.2%, an overall response rate of 87.5%, and a duration of response exceeding 16 months in that patient group.

The poster presentation, titled "Iopofosine I 131 After BTK Inhibitors in Waldenström

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Worksho

Tue, 29 Sep 2026 07:30:00 -0400

Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy

Data Further Support Company’s Plans to Advance Iopofosine I 131 in Phase 3 Confirmatory Trial and Submit for U.S. Accelerated Market Approval in 1H27

FLORHAM PARK, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that a subset analysis

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Worksho

Tue, 29 Sep 2026 07:30:00 -0400

Data Further Support Company’s Plans to Advance Iopofosine I 131 in Phase 3 Confirmatory Trial and Submit for U.S. Accelerated Market Approval in 1H27

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Caligan Partners LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930564.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Caligan Partners LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930564.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26927655.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC

Fri, 14 Aug 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260814/26927655.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26927506.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: STEMPOINT CAPITAL LP

Fri, 14 Aug 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260814/26927506.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924094.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: BALYASNY ASSET MANAGEMENT L.P.

Fri, 14 Aug 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20260814/26924094.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Bleichroeder LP

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921106.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Bleichroeder LP

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921106.html

Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c

Thu, 13 Aug 2026 07:25:19 -0400

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Cellectar Biosciences (CLRB) click here.

Form 8-K Cellectar Biosciences, For: Aug 13

Thu, 13 Aug 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260813/26916433.html

Form 8-K Cellectar Biosciences, For: Aug 13

Thu, 13 Aug 2026 07:25:00 -0400

si-local-file:///var/storage/secattach/20260813/26916433.html

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 13 Aug 2026 07:15:00 -0400

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program

Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical Oncology 2026 Annual Meeting

Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in
Triple Negative Breast Cancer

Announced Publication of Phase 1 Data in Peer-Reviewed Journal Cancers

Company to Hold Webcast and Conference Call at 8:30

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 13 Aug 2026 07:15:00 -0400

Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program

Presented Data from CLOVER WaM Trial of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) at the American Society of Clinical Oncology 2026 Annual Meeting

Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in
Triple Negative Breast Cancer

Announced Publication of Phase 1 Data in Peer-Reviewed Journal Cancers

Company to Hold Webcast and Conference Call at 8:30

Form 10-Q Cellectar Biosciences, For: Jun 30

Thu, 13 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260813/26916258.html

Form 10-Q Cellectar Biosciences, For: Jun 30

Thu, 13 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260813/26916258.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Empery Asset Management, LP

Tue, 04 Aug 2026 10:06:00 -0400
si-local-file:///var/storage/secattach/20260804/26863497.html

Form SCHEDULE 13G Cellectar Biosciences, Filed by: Empery Asset Management, LP

Tue, 04 Aug 2026 10:06:00 -0400
si-local-file:///var/storage/secattach/20260804/26863497.html